GlassScriptPhysician profile
Chris Vasilakis
NPI 1659378081
$720.76
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $146 · 2021: $212 · 2022: $22.68.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $136.99 | 2019-2021 | |
| Bioventus LLC | $132.49 | 2019-2021 | |
| Medical Device Business Services, INC. | $85.70 | 2019 | |
| Depuy Synthes Sales INC. | $68.66 | 2019-2022 | |
| Pacira Therapeutics, INC. | $66.23 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $65.21 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $54.58 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $41.07 | 2019 | |
| Smith+Nephew, INC. | $16.56 | 2019 | |
| Baudax Bio INC. | $14.60 | 2020 | |
| Horizon Therapeutics Plc | $13.09 | 2019 | |
| Csl Behring | $12.95 | 2021 | |
| Fidia Pharma USA INC. | $12.63 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Vasilakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.